The $5.2bn impending merger between Pfizer and Anacor is expected to accelerate the marketing and commercialisation of Anacor’s atopic dermatitis pipeline candidate Crisaborole, according to a report by GlobalData.

Anacor’s Crisaborole was initially planned to be introduced in the US lone, but with Pfizer now on board the drug is planned to be launched globally across all the major markets resulting in a larger patient population for the drug.

The report, titled ‘PharmaPoint:Atopic Dermatitis -Global Drug Forecast and Market Analysis to 2024‘, highlights that competition in the severe atopic dermatitis market will be stiff with the launch of Regeneron and Sanofi’s dupilumab in the second quarter of 2017.

However, the entry of Crisaborole is expected to be smooth as it will be targeted at the dormant mild-to-moderate atopic dermatitis market.

"With a proven safety and efficacy record in treating the paediatric patients, Crisaborole will be a significant drug for this demographic."

Although Crisaborole has the first-mover advantage in mild-to-moderate atopic dermatitis market, it may face competition from Otsuka‘s pipeline candidate, which has been licensed by Medimetriks in collaboration with Knight Therapeutics.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

See Also:

With a proven safety and efficacy record in treating the paediatric patients, Crisaborole will be a significant drug for this demographic.

Ph.D. GlobalData’s immunology analyst Abhilok Garg said: "Pfizer now has the opportunity to build on the work of Anacor by utilising its existing relationships with paediatricians and primary care physicians, and its experience in markets outside of the US.

"Indeed, this insight could serve to aid the company in its development of topical Xeljanz."

Crisaborole’s entry into the US market and six other major markets including France, Germany, Italy, Spain, the UK and Japan is estimated to benefit approximately eight million patients by 2024, of which paediatric or adolescent patients will account for 60%.